Rethinking surveillance after breast cancer
- PMID: 39892894
- DOI: 10.1016/S0140-6736(25)00093-5
Rethinking surveillance after breast cancer
Conflict of interest statement
I have received grants or research support from the Dutch Research Council ZonMW, European Research Council, Horizon Europe, Dutch Cancer Society, EFRO Oost, InHolland, Siemens Healthineers, Bayer Healthcare, Beckton & Dickinson, Screenpoint Medical, Lunit, Koning, and PA Imaging; book royalties from Elsevier; consulting fees from Siemens, Bayer, Guerbet, Screenpoint, and Beckton & Dickinson; honoraria for lectures from Siemens, Bayer, and Beckton & Dickinson; and am a member of the Data and Safety Monitoring Board of the SMALL trial, chair of the scientific committee and member of the executive board of the European Society of Breast Imaging, chair of the Dutch College of Breast Imaging, and member of the editorial boards of Radiology and European Radiology.
Comment on
-
Annual versus less frequent mammographic surveillance in people with breast cancer aged 50 years and older in the UK (Mammo-50): a multicentre, randomised, phase 3, non-inferiority trial.Lancet. 2025 Feb 1;405(10476):396-407. doi: 10.1016/S0140-6736(24)02715-6. Lancet. 2025. PMID: 39892911 Clinical Trial.
Publication types
LinkOut - more resources
Full Text Sources